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91 Introduction 
1.1 General background 
Polycyclic aromatic hydrocarbons (PAHs) constitute a large class of chemical 
compounds that consist of fused aromatic rings. PAHs are lipophilic and relatively inert 
and may be toxic, teratogenic and carcinogenic, depending on the structure and the number 
of rings in the molecule. Lately 15 individual PAH compounds have been classified as 
carcinogens by IARC (1). 
PAHs are formed during incomplete combustion of organic matter and fossil fuels 
in both industrial and natural processes, automobile exhaust, cigarette smoke and well-
prepared and broiled food (2;3). PAHs are hence ubiquitous environmental contaminants 
found in air, water, soil and food. PAHs often exist as complex mixtures and they may 
persist in the environment for a long time. Benzo[a]pyrene (BP) is an important member of 
the PAH family and has served as a model for studies of the metabolic pathway and 
carcinogenic effects of PAHs (4).  
Table 1 gives an overview of the content of BP found in different samples (4-6).  
Type of sample BP concentration 
Air (industry, high levels)  > 10 000 ng/m3 
Air (industry, moderate levels) 100 – 1000 ng/m3 
Air (city levels) 1 - 500 ng/m3 
Soil 0.8 ng/kg – 100 mg/kg 
Tap water 2.5 – 9 ng/L 
Surface water 130 – 500 ng/L 
Plants < 150 000 ng/kg 
Food 100 – 20 000 ng/kg 
Table 1 Concentrations of BP detected in air, water, plants and food (4-6). 
Exposure to PAHs is high in occupational environments like coke production sites, 
aluminum smelters, foundries and in the manufacture of graphite electrodes and refractory 
products (5;7). The workers are exposed to PAH mostly through inhalation and skin 
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uptake. For the population in general the PAH exposure is mainly through consumption of 
food and air pollution including cigarette smoking (5;8). There are several epidemiological 
studies showing the association between PAH exposure and different human cancers 
especially lung cancer, but also bladder, skin, prostate and scrotal cancer (5). Lung cancer 
is today considered the leading cause of cancer death and continues to increase worldwide 
(9). A thorough overview of available published data on carcinogenic properties of 60 
PAH have been summarized in the latest IARC monograph (1). 
1.2 History 
Sir Percival Pott reported the first observations of a possible linkage between 
exposure to coal chimney soot and the occurrence of scrotal cancers among chimney 
sweeps.  The industrial revolution and development introduced new industrial carcinogens, 
like coal tar, paraffin and mineral oils. The first carcinogenic response study were done on 
mice in 1915 by Yamagiwa and Ichikawa (10). In the 1920’s, Kennaway, concluded that a 
hydrocarbon in coal tar, was responsible for the observed carcinogenic properties of coal 
tar. Later Kennaway and Hieger, identified a carcinogenic hydrocarbon as 
benz[a,h]anthracene. Still, it was Cook that finally identified BP as the principal chemical 
carcinogen in tar, in the 1930 (10). 
1.3 The metabolism of BP  
PAH are metabolized by different enzymes in a series of steps, where each step 
forms intermediates that are either detoxified or activated towards reacting with cellular 
components like DNA and proteins. The aromatic and planar ring of BP has different sites 
that are suitable for the action by the microsomal P450 enzymes. The enzymatic oxidation 
inserts one oxygen atom from molecular oxygen into the compound through a NAD(P)H 
dependent catalytic cycle (11). The epoxide intermediate may then be hydrolyzed by 
epoxide hydrolase (EH) or undergo isomerization to phenols.  Hence, different BP phenols 
and BP diols are then formed depending on the type of P450 (Cyp) enzyme and the 
available EH (12;13). The phase II enzymes like UGT and SULT may then further 
conjugate the phenols and diols. The overall process detoxifies the PAH from the organism 
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by reducing the liphophilicity and enhancing the clearance and excretion of the compounds 

























Figure 1 The bioactivation and detoxification of BP by phase I and II enzymes, and the 
formation of the ultimate carcinogenic diol-epoxides. 
The bioactivation of BP includes the formation of mutagenic metabolites, like the 
BP diol-epoxides ( BPDE I), which are strong electrophilic compounds known to be 
highly reactive towards DNA and proteins (12;14;15). In this metabolic pathway, BP is 
initially oxidized by cytochrome P450 to form a BP 7,8-epoxide. The epoxide is rapidly 
hydrolyzed by epoxide hydrolase (EH) to form the proximate carcinogen dihydrodiols, () 
BP 7,8 diols, which may further be oxidized by P450 to form the ultimate carcinogenic BP 
diol-epoxides (16). The P450 produce epoxide groups that are either cis or trans, while the 
EH yields diols that are only trans. Hence, the result is the formation of different BP diol-
epoxide isomers and enantiomers, of which the optically active bay-region  (+) 7,8-diol-
9,10-epoxide enantiomers, i.e. (+) BPDE I, is considered to be the ultimate carcinogen 
(12).  
In early studies it was believed that the K-region BP 4,5 epoxide was one of the 
major carcinogenic BP metabolites (17), but gradually it was found that the epoxide was 
rapidly hydrolyzed by EH leading to the BP 4,5-diol, and other carcinogenic BP 
metabolites were identified (18).  The bay-region theory introduced in the 1970’s helps to 
predict ultimate carcinogenic structures (19). The bay region in the BP molecule is the 
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sterically hindered region formed by the angular benzo ring. The bay-region diol-epoxides 
were found to be more chemically reactive and resistant to hydrolysis by EH and hence 
important in DNA binding and tumorgenisis. (12;16;20). The formation of DNA adducts is 
the first step in the initiation of PAH induced carcinogenesis (21).  
The biotransformation of BP may form BP 9,10 diol, in an analogous way to BP 
7,8 diol, leading to the formation of non-bay region diol-epoxides,  like 9,10-dihydrodiol 
































Figure 2 Diol-epoxide formed from BP. The bay region BPDE I is considered the ultimate 
carcinogen. The  non-bay region diol epoxides, BPDE III, are considered to be less mutagenic 
but highly cytotoxic (22). 
The BPDE III diol-epoxides have been shown to form DNA adducts in-vitro (23), 
although their mutagenic activity have been shown to be very low  as compared to BPDE I 
(24). In addition, metabolic studies with BP 9,10 dihydrodiol show primarily a formation 
of a phenolic compound and only smaller formation of metabolites containing the 7,8,9,10-
tetrahydro-BP chromophore. (24). Toxicity studies shows that BPDE III is highly cytotoxic 
compared to BPDE I (25).  
The main pathway of BP activation involves the action of P450 and EH with the 
formation of diol epoxides as depicted in Figure 3. There are other metabolic routes that 
form several toxic and reactive molecular species. One pathway involves the formation of 
radical cations by P450 peroxidases. These radical cations forms unstable depurinating 
adducts and apurinic sites. The other pathway involves the formation of benzo[a]pyrene-
7,8-dione (BP-7,8-dione) catalyzed by human aldo-keto reductases AKR1A1 and 
13
AKR1C1-AKR1C4 (26). The BP-quinones are reactive Michael acceptors and may react 
with DNA to form either stable bulky adducts or depurinating adducts (27). In addition, the 
BP-quinones can undergo conjugation reactions with endogenous nucleophiles like GSH, 
etc., which can lead to a depletion of cellular reducing equivalents and a change in redox 
state. The ROS that are produced during the redox cycling of BP-7,8-dione can either 
cause oxidative DNA damage or produce decomposition products of lipid hydroperoxides, 
which are also reactive towards DNA (28). 
BP radical cation









Figure 3 Metabolic activation of BP by P450 and AKR isoforms. 
Several BP diones-DNA adducts have been characterized in vitro (29), and the 
metabolic activation of BP by the AKR pathway is believed to add to the initiation of PAH 
induced carcinogenesis (30). 
1.4 The adduct formation 
The major sites of attachment for the bay-region diol epoxides in DNA are the 
exocyclic amino groups of deoxyguanosine, deoxyadenosine and to a very small extent 
cytosine (31;32). The diol epoxide adducts are formed by both cis and trans opening of the 
epoxide at the benzylic position, hence eight dA and eight dG isomeric adducts are 
possible (33). Theoretical computations along with NMR and X-ray crystal studies have 
been used to elucidate several structures of different BP-DNA adducts. See Figure 4. The 
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isomers and enantiomers of the diol epoxides have been shown to have different biological 
activities, like adduct formation and mutagenic activity, depending on the test system used 
(12). Several studies using different cell systems have demonstrated that the ultimate 
carcinogenic BPDE I bind more to DNA and proteins, than BPDE II and BPDE III 
(12;25;34). The BPDE I shows a high base selectivity towards deoxyguanosine in double 
stranded DNA that result in mainly BPdG adducts (35). The (+) BPDE I enantiomer has 
been found to bind to the 2-amino group of deoxyguanosine to a 20-fold greater extent 
than the (-) BPDE I enantiomer. (36). In the absolute configuration and conformation of 
the BPdG adduct, the exocyclic amino group is bound to the C10 position of the diol 
epoxide, in either a cis or a trans position relative to the hydroxyl group in the C9 position. 
The C7 and C8 hydroxyl groups are pseudodiaxial in the cis product and 
pseudodiequatorial in the trans product (37;38). The studies shows that the adducts are 
located in a minor groove and directed towards the 5’end or the 3’end of the modified 
strand (39). Interestingly, although there is flexibility around the C2-N2 bond of guanine 
and the N2-C10 position between guanine and the diol epoxide, the adducts have strong 
conformational preferences (40). Both the structure and conformation of the BP-DNA 
adduct is believed to influence their interactions with the DNA repair enzymes affecting 
the reparability and removal rate of the BP-DNA adduct, and ultimately the risk of 
mutation (40;41). 
When the DNA adduct remains unrepaired, they can cause a miscoding during the 
replication by inducing transversion mutations involving both G and A, and hence produce 
a permanent mutation (42).  If the mutation occurs in a critical region of important genes, 
like oncogenes and tumor suppressor genes, a chemical induced cancer may occur (43). 
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Figure 4  The BP-DNA adduct between (+) BPDE I and the exocyclic N6-amino group of 
deoxyadenosine. The picture illustrate the BP-DNA adduct inside the major groove of the 
DNA duplex. Picture adapted from NCBI using Cn3D (33). 
Hence, the BP-DNA adducts are well suspected of producing mutations, in specific 
G to T transversions, within codons of the p53 tumor suppressor gene and the K-ras proto-
oncogene in lung cancer (43-45).  
1.5 The cytochrome P450 
The cytochrome P450 is a group of hem-thiolate mono-oxygenase enzymes, 
encoded by the superfamily of P450 CYP genes. It was first discovered in rat liver 
microsomes in the beginning of the 1950’s, having a unique spectral absorbance band with 
a peak around 450 nm (46). Later on, in the 1960’s it was characterized as a hemprotein
and the catalytical properties were studied. Today over 1000 P450 genes have been 
identified, cloned and expressed in heterolgous expression systems.  The P450 genes are 
found in the genome of virtually all organisms. Yeast has three, Mycobacterium 
tuberculosis has 20, humans have 57 while their number has exploded in plants (47). 
Although the amino acid sequences are very diverse, the catalytic properties with haem-
thiolate binding using cysteine have remained the same throughout evolution. The P450 
are involved in a diversity of processes from highly regio- and sterospecific to very diverse 
reactions like carbon source assimilation, biosynthesis of hormones and fat-soluble 
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vitamins, and oxidation of endogenous and foreign compounds (48). The most important 
P450s in the metabolism of PAH in mice and rodent are the Cyp1a1 and Cyp1b1. 
Historically, the Cyp1a1 has been attributed to the metabolic activation of PAH in mice 
and rodent models (12;49). Cyp1a1 is constitutive expressed at low levels in liver and 
different organs, but is highly inducible. Recent studies have shown that Cyp1b1, which is 
expressed at higher levels in extra-hepatic organs, may also be important in the activation 
of PAH (50). Other studies has shown that Cyp1b1 is more important than Cyp1a1 in the 
first activation step of BP and the formation of BP 7,8 diol (51).  
The P450 enzymes catalyze about 90 % of the phase I metabolism in humans. The 
major catalysts of foreign compounds in human liver are CYP3A4, CYP2D6, and CYP2C 
subfamilies (52).  The Cyp1a1, which is the major catalyst of BP in rodent liver, is almost 
absent in human liver (53). The mice Cyp1a1 activity has been shown to be 40 times 
higher than any human P450 enzymes in metabolizing BP to BP 7,8 diol and BP diol-
epoxides (13). As in rodents, human CYP1B1 are expressed in different tissues. Studies 
have demonstrated that CYP1B1 is active in the endogenous steroid metabolism, but do 
also play a role in the metabolism of environmental PAH compounds. In contrast to rodent 
cyp1b1, human CYP1B1 show lower rates of BP metabolism (54). Hence, human and 
rodent P450 can display large differences in activities (52). Different studies with isolated 
human P450 enzymes have shown that several P450 enzymes, i.e.  CYP1A1, 1B1, 1A2, 
3A4, 2B6, 2C9, 2E1 and 2B6 are capable of oxidizing BP (13;53;55).  Some of the 
enzymes and the metabolic pathways may be detoxifying, like the formation of 3OH-BP 
by CYP3A4 (55). Although the metabolic pathway may be dependent on the in vitro
system and the amount of EH, the CYP1A1 seems to have the highest turnovers for the BP 
metabolism. In addition, CYP1B1, CYP1A2 and CYP2C9 seem to have a high activity for 
the formation of BP 7,8 diol and BP diol epoxides (13;53;54). The P450s controls the 
stereoselectivity of the formed BP metabolite, and the balance between activation and 
detoxification of the PAH compound.  Hence, an important aspect of the PAH metabolism 
by the P450s, includes the different genetic polymorphisms of P450s, that may affect the 
individual susceptibility to PAH carcinogenesis (56;57). 
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1.6 Phase II – detoxification 
BP is metabolized to various products by the xenobiotic metabolizing enzymes. 
These enzymes are divided into phase I and phase II enzymes. The microsomal P450 phase 
I enzymes produce a complex mixture of quinones, phenols, dihydrodiols, triols, pentols 
but also reactive epoxides (58). The phase II enzymes glutathiontransferase, 
glucoronosyltransferase and sulfotransferase (SULT) will further act on the oxidized 
products from the phase I step, and form conjugates of glutathione, glucoronide and 
sulphate. The formation of highly polar and water-soluble metabolites increases the 
excretion of BP from the body into urine and bile Although, the sulphate conjugation is 
regarded as an important detoxification pathway, there are several compounds that are 
further activated by forming electrophilic sulphuric ester metabolites (59-61). There are 
reports of different polymorphisms in SULT1 associated with the risk of lung cancer (62-
64). There are also studies showing an additional increase in risk for colorectal cancer with 
certain combinations of Cyp1b1 and SULT1 polymorphism (65).  When the sulphuric ester 
loses the sulphur group it forms an extremely reactive carbocation. This ion may then react 
spontaneously with DNA or other cellular components leading to serious toxic lesions and 
mutations (60;61). A group of compounds that have been shown to be activated both in 
vivo and in vitro experiments by sulphotransferase are methyl-substituted PAHs and 
nitrosamines. Hence, the potential sulfonation of related PAH metabolites like the BP diols 
and BP tetrols is of interest since such a pathway could reactivate the metabolites (61). 
Different studies have shown that sulfonation of BP diols in vitro is possible although less 
efficient than with BP phenols. Studies withV79 hamster cells expressing sulfotransferase 
showed an induction of chromatid exchange after BP tetrol exposure. A different study 
showed that BP diol and BP tetrol did not exhibit any sulfotransferase dependent 
mutagenicity nor any DNA adducts formation (66). Nevertheless, it remains unclear 
whether this pathway contributes to the overall carcinogenicity of BP (66).  
1.7 The aryl hydrocarbon receptor  
The aryl hydrocarbon receptor (Ahr) is a ligand activated member of the per-arnt-
sim (PAS) family basic-helix-loop transcription factors and is located in the cytosol in 
association with heat shock HSP(90) and HSP90 accessory protein (67). 
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The activation of Ahr results in rapid transcriptional activation of numerous genes 
that control a broad spectrum of cellular functions. Ahr is involved in endogenous 
physiological and developmental processes but also toxicological processes and oxidative 
stress (68).  
BP and other PAH are primarily activated in the body by the Ahr, which acts as a 
transcriptional factor of several important xenobiotic genes. BP acts as ligand and binds to 
the Ahr in the cytoplasm. See figure 5. The liganded Ahr is then translocated to the nucleus 
where it forms a heterodimer with the Ahr-nuclear translocator (Arnt) (69). The Ahr/Arnt 
heterodimer recognize and bind to xenobiotic responsive element (XRE) sequences located 
in the promoter region of several genes such as cytochrome P450 Cyp1a1, Cyp1a2, 
Cyp1b1, glutathione S-transferases (Gst), UDP-glucoronoysyl-transferases (Ugt) and 
quinine oxidoreductase. The binding results in transcriptional activation of the genes and 
induction of phase I and phase II metabolizing enzymes as well as phase III transporter 
proteins (70). The relative expression of these enzymes will determine the degree of 

























































Figure 5 Mechanism of transcriptional activation by Ahr. 
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The activation of Ahr has also been shown to antagonize other nuclear hormone 
proteins like the estrogen receptor (ER). Recently, it has been shown that ER- may 
interact directly with the Ahr, hence inducing both Cyp1a1 and Cyp1b1 in human 
bronchial epithelial cells (71). Since ER- is often more expressed in the lungs of women 
than of men, this could partly explain the observed gender differences in lung cancer 
susceptibility (72-74).  At the same time TCDD, which is a high affinity ligand for Ahr, 
has been shown to inhibit estrogen metabolism. The result is an inhibition of the ER-
regulated gene expression (75). The inhibitory Ahr-ER cross-talk has been demonstrated in 
breast cancer cells and may prove valuable for the development of Ahr modulators for 
treatment of breast cancer (76).   
1.8 Mice models 
The discovery of the involvement of the cytochrome P450 Cyp1a1 and the Ahr 
signaling pathways in the metabolism of PAHs has led to several studies with Ah-
responsive/non-responsive mice, and Cyp- and Ahr-knockout mice models.  
Ah-non-responsive mice exposed to BP by topical application or intraperitoneal 
(i.p.) injection showed lower risk of mutagenesis and carcinogenesis than Ah-responsive 
mice (69). When the PAH was administered orally, the Ah-non-responsive mice 
experienced higher toxicity and tumor formation in organs distal to the site of 
administration, while the Ah-responsive mice experienced increased toxicity and tumor 
induction in organs at the site of administration. In addition, the Ah-non responsive 
showed reduced survival time compared with Ah-responsive mice (69). These results were 
explained by the first-pass effect  (69;77). 
Similar observations were made with knockout mice models of Cyp1a1, Cyp1a2 
and Cyp1b1. Knockout mice exposed to BP by i.p or oral injection experienced higher 
levels of toxic lesions and higher mortality rates. In addition, the knockout mice showed a 
slower clearance of BP and increased levels of BP-DNA adducts than the wild-type mice 
(77-80). These studies concluded that the Ahr-inducible Cyp1a1 and Cyp1b1 play 
important and possibly different roles in the activation and the detoxification of BP (80). 
In Ahr knockout mice studies by Shimitzu et al. (81), they reported that the Ahr(-/-) 
mice were more resistant to BP induced toxicity and cancer. The mice received topical 
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application and subcutaneous injection of the PAH, and only the Ahr wild-type mice 
developed tumors at the end of the experiment. In a different Ahr knockout mice study, 
Kondraganti et al. (82) exposed two mice groups, Ahr(-/-) and Ahr(+/+), to a single i.p. 
dose of BP. They then observed the formation and distribution of DNA adducts in the liver 
by 32P-postlabelling, Interestingly, the hepatic DNA adduct levels were different between 
Ahr(-/-) and Ahr(+/+), but the total sum of hepatic BP-DNA adducts were the same, a 
result pointing towards an Ahr independent BP activation in the mice liver  (82). These 
studies show that end responses, such as toxicity, lethality and DNA adduct formation, are 
clearly dependent on both the dose and the route of administration. 
1.9 Analytical techniques  
Different methods have been used to study DNA and protein adducts, like 
postlabelling, immunoassay, and HPLC. The BP-DNA adduct formation is usually low; i.e. 
1 in 106 to 1 in 107 bases (83). The 32P-postlabeling has been the most sensitive method to 
measure BP-DNA adduct (84). The limit of detection (LOD) is as low as 1 adducts/1010
nucleotides, but due to lack of structural information other methods are implemented (85). 
GC-MS has successful been applied for the determination of protein adducts (86). Lately, 
HPLC coupled with fluorescence or MS, has been used, reducing the sample preparation 
time and loss of sample due to derivatization (84;87;88).  In addition, valuable structural 
information may be obtained by studying the entire BP conjugates and phase I BP 
metabolites by HPLC (89;90). 
1.10 Epimerization 
The hydrolysis of the DNA and protein adduct, releases the corresponding diol-
epoxides as four specific BP tetrols (91). Hence, the BP tetrols measurements reflect the 
formation of specific reactive diol-epoxides and gives valuable information of the 
metabolites formed in the metabolism of BP (84). Unfortunately, the hydrolysis condition 
employed to release the BP tetrols, leads to an epimerization between the BP tetrols 
(92;93). This chemical equilibrium reaction is the result of an isomerisation in particular at 
the C10 hydroxyl group in the BP tetrol molecule and is very much dependent on the pH of 














Figure 6 Acid hydrolysis of protein and DNA adducts and the epimerization at C10. 
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2 Aims of study 
• Explore the use of miniaturized LC-MS with large volume injection as a sensitive 
analytical technique with structural information in the analysis of BP tetrols. 
• Identify the mass of two BP protein adducts formed in vivo in rats exposed to BP. 
• Study the relationship between the Ahr and the metabolism of BP in Ahr knockout 
mice and Ahr wild type mice. 
• Study the effect of time and the administration route on the metabolism of BP in 
Ahr knockout mice and Ahr wild type mice. 
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3 Material and methods 
3.1 Chromatographic conditions 
Solid phase extraction with C18 cartridges was used for sample clean-up and pre-
concentration to reduce time as well as consumption of organic solvents.  
In Paper I, the LC analysis was performed on a capillary HPLC System with 
capillary C18 columns, coupled with a UV-diode array detector and a tandem quadrupole 
mass spectrometer.  The mass spectrometer was equipped with a Z-spray atmospheric 
pressure ionization ion source prepared for electrospray ionization (ESI). 
The large volume injection was achieved by coupling column switching with an 
isocratic capillary pump.  In Papers II-IV, the analysis was performed on conventional 
HPLC attached with a fluorescence detector and where needed a fraction collector. 
The use of HPLC in sample analysis and sample collection is highly efficient and specific. 
The automatic fraction collection system was used for adducts purification and metabolites 
determinations throughout the study. 
3.2 Cell and animal models 
Human  hepatoma cell lines HepG2,  obtained from the American Type Culture 
Collection (Manassas, Virginia, US), were used in paper I. 
In Paper II we used male Wistar rats (B & K Universal AS, Norway) weighting 
about 230 g. 
In Papers III and IV we used Ahr heterozygote mice (C57BL6), that were obtained 
from the Department of Pathology, Graduate School of Medicine, University of Tokyo, 
Japan. The Ahr (+/-) were interbred to generate Ahr (+/+), Ahr (+/-) and Ahr (-/-) mice.  
The formation of the knockout offspring did not follow the Mendelian law, since 
repeatedly only about 10-15 % of the offspring had the Ahr (-/-) genotype. Real-time RT-
PCR measurement of AHR expression was carried out on lung tissue samples at the end of 
the experiments to verify genotypes (81). There were no observed differences in growth 
rate and appearance between the different genotypes.  
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3.3 BP exposure 
The HepG2 cells were grown to confluence and then exposed to 20 mM BP for 2 
days. The medium solution was recovered at the end of the incubation period and aliquots 
were further taken for sample preparation.   
The Wistar rats were treated with a single i.p.dose of BP (100 mg/kg) for 
identification of the novel BP protein adducts. After 3 days, the animals were anesthetized 
and drained for blood.  
In Paper III, the Ahr mice groups were treated with a single oral dose of BP (100 
mg/kg). Internal organs were collected after for 24 hours.  In Paper IV, the Ahr wild mice 
and Ahr knockout mice were exposed to a single dose of BP, by two administration  
routes; intra peritoneal (i.p)  and cutaneous, for 24 hours. In addition, Ahr mice groups 
were treated with a single oral dose of BP. The animals were placed in cages overnight, 
with subsequent collection of urine and feces.  The mice groups were then sacrificed at 
different time points.   
3.4 BP conjugates 
In Paper III we measured both sulphate conjugates and glucoronide conjugates of 
BP phenols directly using HPLC fluorescence detection. The conjugates were isolated 
from BP exposed mice urine, and the individual fractions were subjected to enzymatic 
hydrolysis with glucoronidase/arylsulphatase. In addition, BP sulphates were prepared in 
vitro by conjugating the corresponding BP phenols with arylsulphatase and PAPS (66). 
3.5 Cytochrome P450 
Gene expression measurements of Cyp1a1 and Cyp1b1 were carried out by 
quantitative real-time RT-PCR on an ABI PRISM 7900 (Applied Biosystems). The 
specific gene expression levels were then normalized to the expression of -actin.   (95).  
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4 Summary of papers 
4.1 Paper I 
The aim of Paper I was to develop an analytical method with the use of a 
miniaturized LC system coupled with a column switching system with large volume 
injection of samples. The detection was performed with coupled on-line ESI-MS and 
fluorescence detectors. A well-established off-line crude solid phase extraction procedure 
was first used in order to make the method compatible with several biological matrices. 
The method was validated over the concentration range 0.1–50 ng/ml benzo[a]pyrene 
tetrols in a cell culture medium with 100 ml injection volume, fluorescence detection and 
the first eluting tetrol isomer as model compound. The mass limit of detection (by 
fluorescence) was 3 pg for all the tetrol isomers, corresponding to a concentration limit of 
detection of 30 pg/ml cell culture medium. The corresponding mass spectrometric mass 
limits of detection were 4–10 pg, corresponding to concentration limits of detection of 40–
100 pg/ml cell culture medium. The capillary column enhances mass sensitivity due a 
reduced dilution of the chromatographic band, and further improvements in sensitivity are 
possible with the use of large volume injections. The method was shown to have good 
selectivity and sensitivity towards determination of BP protein adducts.   
4.2 Paper II  
The aim of Paper II was to determine the mass of two novels protein adducts in BP 
exposed rats. The two protein adducts were isolated from the acid hydrolysis of serum 
albumin from BP exposed rats, and identified as BP tetrols with the use of a miniaturized 
LC-ESI-MS system.  The retention time and the fragmentation patterns were characteristic 
of tetrols with formation of the molecular ion and the loss of water molecules. In addition, 
we observed a fluorescence spectrum for the isolated compounds that where characteristic 
for the tetrols. The isolated compounds were also each subjected to acid hydrolysis that 
gave rise to an epimerization between the two unknown tetrols and BPDE II. This 
epimerization reaction probably involved the OH groups in position C10-OH and C7-OH of 
the molecule. The two novel tetrols should then have the C7-OH and C8-OH groups in a cis
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position. The presence of the cis adducts in vivo are probably the result of the formation of 
BPDE III in the metabolism of BP. 
4.3 Paper III 
The aim of Paper III was to study the relationship between the metabolism of BP 
i.e. the formation of BP adducts and metabolites and the Ahr genotype in mice. Gene 
expression measurements on Cyp1a1 and Cyp1b1, showed induction of Cyp1a1 and 
Cyp1b1 in both Ahr(+/+) and Ahr(+/-) but no induction of the Cyp genes in the Ahr(-/-). 
There was a significant basal expression of Cyp1b1 in the liver of all genotypes, and this 
expression was independent of BP exposure. HPLC measurements showed increased levels 
of protein and DNA adducts, metabolites, conjugates and unmetabolized BP in the internal 
organs of the Ahr(-/-) as compared to the two other genotypes.  These results were 
indicative of an Ahr independent and/or a slower biotransformation of BP in mice lacking 
the Ahr. 
4.4 Paper IV  
The aim of Paper IV was to confirm a slower biotransformation of BP in Ahr 
knockout mice and also compare the effect of administrations routes. A time course 
experiment for six months was conducted with animals that received a single oral dose of 
BP. The Ahr(+/+) mice appeared to have an effective clearance of BP metabolites in the 
feces, mainly through 3-hydroxybenzo[a]pyrene and 9-hydroxybenzo[a]pyrene, hence 
reducing rapidly the levels of DNA and protein adducts in the internal organs. Contrary to 
this, the Ahr(-/-) mice showed higher levels of DNA and protein adducts in the internal 
organs during the time course experiment. The Ahr(-/-) mice also experienced a slower 
excretion of metabolites in the urine and feces compared to the Ahr(+/+) mice. These 
results confirmed a slower biotransformation of BP in the Ahr(-/-) mice. We also 
performed an administration route experiment and found that skin-exposed Ahr(+/+) mice 
showed higher levels of protein adducts, but only in the exposed skin area as compared to 
the Ahr(-/-). In the non-exposed skin the adduct levels were the same between the two 
mice groups. These results showed that the distribution and levels of BP and BP-protein 
adduct in the Ahr(-/-) mice are clearly dependent on the route of exposure. Although not 
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published, we also found that the Ahr(-/-) mice showed higher levels of metabolites in the 
examined tissues than the Ahr(+/+) mice. In addition, the conjugate levels were almost the 
same between the Ahr(-/-) and Ahr(+/+) mice. 
5 Discussion 
PAH are ubiquitous environmental pollutants found in soil, sediments, water and 
air. BP is one of the most carcinogenic and genotoxic members of the PAH family. 
Humans are exposed on a daily basis to PAHs either through the working environment 
and/or through diverse sources such as polluted air, water, food and cigarette smoking. 
When assessing the health risk of BP and other PAHs  there is a need for both analytical 
methodologies to detect and measure the BP adducts and  BP metabolites, but also for the 
need of better understanding the metabolism of the compound in the body. 
5.1 Analytical aspects and biomarkers 
Biomarkers are valuable tools to assess the health risk of exposure to toxic 
chemicals. BP protein adducts correlate with BP DNA adduct formation and are not 
subjected to enzymatic repair as DNA (91;96). Hence, the BP protein adduct concentration 
is generally higher than the BP DNA adduct concentration, which makes the BP protein 
adducts more sensitive biomarkers to assess and estimate exposure dose (97). In 
occupational environments, like coke production sites, aluminum smelters, and foundries, 
the workers are subjected to an exposure for different PAH mixtures, as explained in 
section 4.1 Therefore it is important to have adequate analytical methods to determine the 
compounds and their metabolites in body fluids like urine and blood.  
Miniaturized analysis schemes are today routinely applied in several applications, 
and offer some advantages over conventional HPLC like reduced consumption of mobile 
phases, stationary phases, reduced analysis time and easy coupling with MS (98). On the 
other hand, the higher LODs and sometimes lack of robustness still challenges the 
miniaturizing techniques. In Paper I, we implemented a miniaturized HPLC system with 
packed capillary LC columns and large volume injection, coupled with ESI-MS to 
determine BP protein adducts. The method involved hydrolysis of BP protein adducts, and 
the release and measurements of the BP tetrols. The small dimensions of the capillary 
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columns (0.3x150 mm) offered enhanced mass sensitivity due to reduced dilution of the 
chromatographic band. In addition, the small 3.5 µm particles of the packed column, 
offered both an increase in selectivity and efficiency as compared to conventional HPLC 
packed columns (99).   The method was further optimized for large volume injections of 
samples, with a sample focusing step and a further improvement of the concentration 
sensitivity. The method also included an off-line SPE step for a crude sample clan up, 
making the method compatible with different biological matrices. Wang et al had 
previously demonstrated the use of miniaturized LC-MS for identification and 
characterization of urinary BP metabolites from mice and rat; however, they did not exploit 
the potential of large volume injections to improve concentration sensitivity (100;101).  In 
total, the miniaturized LC-ESI-MS technique offer good selectivity and sensitivity and was 
promising for measurements of low-dose PAH exposure in complex matrices and with 
limited available samples. 
In Paper II, two novel protein adducts were isolated from BP exposed mice, 
probably formed from a non-bay region diol epoxide. The two adducts where further 
characterized as BP tetrols by the use of mass spectrometry and fluorescence spectral data. 
The degree of fragmentation in ESI is soft compared to other ionization techniques in MS. 
Hence, the most important ions for characterization of the tetrols were the molecular ion 
and two characteristic water loss fragments. In addition, fluorescence measurements of the 
two adducts have indicated that the fluorescence excitation and emission spectra were 
characteristic of the tetrols (92). We performed several acid hydrolysis reactions with the 
isolated novel BP tetrols, and observed a rapid interconversion between the two novel BP 
tetrols. The BP 7,8 cis tetrol 2 (X2) epimerizes rapid in favor of the other novel BP 7,8 cis 
tetrol 1 (X1). This in pair interconversion has previously been shown for the other four 
tetrols and is the result of the reversible epimerization of the C10 hydroxyl group during 
the acid hydrolysis (86;93).  When we further increased the temperature of the reaction 
mixture, we also observed the presence of two other peaks, which were identified as BP-
tetrol II-1 and BP-tetrol II-2. A similar pattern was observed when starting the acid 
hydrolysis with only BP-tetrol II-2.  BP-tetrol II-2 reached a rapid and constant equilibrium 
with BP-tetrol II-1. When increasing the temperature, two other peaks arise, which were 
identified as BP-7,8 cis tetrol 1 and BP-7,8 cis tetrol 2. Based on our hydrolysis study, and 
the possible epimerization sites in the BP tetrol molecule (93), we proposed that our 
observations probably involved an epimerization of the C7 hydroxyl group in the BP 
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tetrols. The two tetrols should then have the hydroxyl groups in position 7 and 8 in a cis 
position, and they are most likely formed from a non-bay region diol epoxide, i.e. BPDE 
III. This epimerization pattern is depicted in Figure 7. In vitro studies in our lab with 
BPDE-III have confirmed that BPDE III is a precursor to the BP-7,8 cis tetrols (92). 
Figure 7 Epimerization at position C7 and C10. 
The general attention regarding BP diol epoxide formation has been on the 
carcinogenic bay-region diol epoxides (BPDE I and BPDE II). The biotransformation of 
BP forms several reactive diol epoxides, like the non-bay region diol-epoxides (BPDE III). 
Although, diol epoxides like BPDE III are more easily detoxified by EH, they are still 
cytotoxic (22;25), and have also been shown to form DNA adducts (102).  As we have 
demonstrated in our study, several BP tetrols are formed when hydrolyzing serum albumin 
from BP exposed rats. Among these BP tetrols, we have been able to identify two novel BP 
tetrols. The BP tetrols may serve as important exposure markers for BP, hence we 
proposed to also include the two BP-7,8 cis tetrols when possible.(94). The biological 
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between BP-tetrol II-1 and BP-tetrol II-2. In addition it must be necessary to account for 
the sum of BP-7,8 cis tetrol 1 and  BP-7,8 cis tetrol 2. 
5.2 Metabolism of BP in Ahr knockout mice 
The Ah receptor is central in the induction of the Cyp1a1, hence Ahr knock out 
mice are valuable animal models to study the metabolism of BP. 
In Paper III we investigated the relationship between the Ahr genotype and the 
biotransformation of BP and the formation of BP adducts in internal organs. In our study, 
the Ahr mice received only a single oral dose of BP. The Ahr(-/-) mice showed higher 
levels of BP protein and BP DNA adducts in addition to a high accumulation of 
unmetabolized BP, than both Ahr (+/- ) and Ahr(+/+) mice. Since BP adducts may be used 
as cancer risk markers it was an interesting result considering that Ahr(-/-) mice have been 
reported to be more protected against BP induced cancer (81).  Nakatsuru et al. (81)  
observed that Ahr knockout mice had  reduced tumor formation compared to the Ahr wild 
type mice. The mice received BP intraperitoneal or by topical application. Apparently, our 
results indicated the presence of a slow and Ahr independent biotransformation of BP, 
possibly involving constitutive Cyp1b1, and other Cyp isoforms, like Cyp2-4. 
 Kondraganti et al. (37) found that an i.p. dose of BP induced formation of equal 
amounts of hepatic BP-DNA adducts in both Ahr (+/+) and Ahr (-/-) mice. Although BP 
did not induce Cyp1a1/1a2 in Ahr (-/-), they showed basal expression of Cyp1a1/1b1 in 
both Ahr (+/+) and Ahr (-/-) liver. Based on these results they proposed the existence of 
Ahr independent bioactivation of BP in the knockout mice. Interestingly, Shimada et al. 
(103) found that Cyp1b1 was expressed at significant levels in different extrahepatic 
tissues in both Ahr(+/+) and  Ahr(-/-) mice. In addition, they proposed that Cyp1b1 may be 
more important than Cyp1a1 in the first step oxidation of BP and the formation of the BP 
7,8 diol (103;104).  In our study, we measured constitutive basal levels of Cyp1b1 in both 
the lung and liver of the Ahr(-/-), that in part can account for the observed metabolism of 
BP. In other studies, Galvan et al (50;105) have demonstrated that constitutive levels of 
Cyp1b1 in the bone marrow of Ah non-responsive mice probably affect the metabolism 
and the toxicity of BP in the bone marrow. Ah non-responsive mice that received a single 
i.p. dose of BP were found to have a severe bone marrow depletion compared to Ah 
responsive mice.  In early studies by Nebert et al. (69;106;107) they found that Ah 
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responsive mice survived an oral BP exposure for 6 months and longer, while the Ah non 
responsive mice died within 3 weeks.  The cause of death was identified to be a chemical 
induced acute depletion of the bone marrow. When administered orally, BP passes through 
the intestine and enters the bloodstream and the liver. Both the intestine and liver have a 
substantial and well known metabolizing capacity, resulting in the “first-pass effect” (108), 
leading to a presystemic elimination of BP. In particular, the induction of Cyp1a1 in the 
liver of the Ah responsive mice, leads to an efficient metabolism and clearance of BP. 
Other organs believed to perform a substantial first pass metabolism are the lung and skin 
(108). The first pass effect protected the animal by reducing the systemic uptake of BP in 
the Ah responsive mice (69;105;106). In our study, the organs of the Ahr(-/-) mice distal to 
the stomach (site of administration) like lung and spleen, showed the highest levels of 
unmetabolized BP. The lack of a first-pass protection in the Ahr(-/-) mice could explain the 
higher levels of BP accumulated in the internal organs. Similar observations were made 
with knockout mice models of Cyp1a1, Cyp1a2 and Cyp1b1. Knockout mice exposed to 
oral doses of BP had higher mortality rates, and showed higher levels of DNA adducts and 
a slower clearance of BP than the wild type mice (79;80). Apparently, this indicated that 
the induction of Cyp1a1 was protective and more important in the detoxification than the 
bioactivation, while the induction of Cyp1b1 was more important in the bioactivation of 
BP (77). The higher adducts levels in the knockout mice were explained by a reduced 
phase II conjugation due to a loose coupling between the metabolizing enzymes in the 
knockout mice and the phase II conjugating enzymes (77). Interestingly, in our study the 
Ahr(-/-) showed higher levels of BP protein adducts, and of both BP conjugates and BP 
metabolites, mainly free BP tetrols and BP diols, which may point towards an overall 
reduced phase II conjugation in Ahr(-/-) mice (109). Hence, the presence of a functional 
Ah receptor in the Ahr(+/+) mice appeared to be protective, i.e. BP is metabolized and 
detoxified more efficiently with a reduced formation of BP protein and BP DNA adducts 
compared to the Ahr(-/-) mice (109). Meanwhile, the Ahr(-/-) mice should have an higher 
risk in developing genotoxic effects compared to the Ahr(+/+) mice.  
In Paper IV we extended the oral exposure regimen and performed a time-course 
experiment for 6 months with mice that received a single oral dose of BP. The Ahr(-/-) 
mice were found to have higher levels of BP DNA and BP protein adducts, and 
unmetabolized BP in all the internal organs. Peak levels of BP DNA adducts in lung were 
detected after 5-7 days in the Ahr(-/-), whereas the highest levels were observed after 3-5 
days in the Ahr(+/+). The results confirmed that Ahr(-/-) mice have a low metabolic 
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clearance of BP, while the Ahr(+/+) mice have an effective clearance of BP, mainly 
through 3-OH-BP and 9-OH-BP in the feces in accordance with first pass effect. The 
Cyp1a1 in different mice studies has been shown to be much more active than any other 
P450, and the main metabolites formed from BP are BP phenols, mainly 3-OH-BP and 9-
OH-BP (13). 
The effect of the exposure route on the pharmacokinetics uptake and metabolism of 
BP has been previously shown on Ah responsive and Ah non responsive mice (106). If BP 
is given topically, i.p, or subcutanously, the Ah responsive mice are at greater risk for 
toxicity and developing tumors at the site of application (106). On the contrary, when BP is 
given orally, the Ah non responsive mice are at greater risk for bone marrow toxicity, as 
previously mentioned.   
We compared two routes of administration, e.g.  topical and i.p. exposure to BP. 
When the dose was applied topically, the Ahr(+/+) mice showed higher levels of BP 
protein adducts in the exposed skin area. In addition, in the exposed skin area of the 
Ahr(+/+) mice, the formation of BP metabolites followed the order BP phenols>BP 
diols>BP tetrols. In contrast, in the internal organs of the Ahr(-/-) mice the BP protein and 
BP DNA adduct levels were higher than in the Ahr(+/+) mice. These findings show that 
the skin of the Ahr(+/+) mice is able to metabolize BP to a much higher extent than the 
skin of the Ahr(-/-), with a resulting increase in the BP-protein adduct levels locally, and a 
reduced systemic uptake of BP in the Ahr(+/+). Since BP-protein adducts may be used as 
cancer risk markers, our results may support the findings of Nakatsuru (36). When a single 
i.p dose was given, the Ahr(-/-) and Ahr(+/+) mice showed similar levels of BP-protein 
adducts in the internal organs and the skin. In addition, the BP levels in the internal organs 
were almost the same between Ahr(-/-) and wild-type mice (+/+), with exception of the 
lung.  The protein adduct measurements are in agreement with the findings of Kondraganti 
et al. (37), who observed that the total hepatic BP-DNA adduct levels, as measured by 32P-
postlabelling, were equal between Ahr (-/-) and Ahr(+/+) after a single i.p. dose of BP.  
In our studies, the Ahr(-/-) mice showed higher levels of BP protein adducts 
compared to the Ahr(+/+) mice, and of both BP conjugates and BP metabolites, in both 
administration routes. These observations together with the results from the oral 
administration study in Paper III shows that the Ahr(-/-) mice seemed to have an overall 
reduced phase II conjugation compared to the Ahr(+/+) mice.  
 Thus in the absence of a functional Ahr receptor, and a proper induction of 
Cyp1a1, there appears to be a lower metabolic clearance of BP resulting in increased levels 
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of BP protein and BP DNA adducts and metabolites in the Ahr(-/-) mice. There are other 
oxidative enzymes, like constitutive Cyp1b1 and Cyp2, that may account for the observed 
BP metabolism in the Ahr(-/-) mice.  The constitutive levels of Cyp1b1 appear to be high 
in the Ahr(-/-) mice as our result shows. Different studies with other mice groups have 
shown that Cyp1b1 is capable of metabolizing BP to the ultimate carcinogenic diol-
epoxide, although at lower rates than Cyp1a1 (49). Our results may indicate that the role of 
the Cyp metabolism may be more important in detoxification than metabolic activation as 
other mice model studies also show (110).   
34
6 Concluding remarks 
The work presented in this thesis has focused on two subjects related to the PAH 
science. One part has been the development of analytical methods to measure BP adducts 
and metabolites in different matrices. The other part has been to understand the 
relationship between the Ah receptor and the metabolism of BP in mice.  
The miniaturized LC-MS system with capillary column switching proved to be an 
adequate technique in determining BP tetrols in different matrices. One of the major 
concerns regarding miniaturizing techniques has been the limit in the amount of sample 
that can be injected into the system. The use of a capillary column switching system with 
large volume injection circumvented this problem and improved further the sensitivity. 
Hence, the method has a potential use for measurements of low-dose PAH exposure of 
workers in different industries. Lately, the number of both users and applications in 
miniaturized LC has grown in areas where the amount of sample is limited or the analytes 
of interest are in low concentrations.  Another important achievement with the technique 
was the determination of the molecular mass of two new BP adducts isolated in plasma 
proteins from BP exposed rats. These new BP adducts where shown to have the same 
molecular masses as BP tetrols. Epimerization studies gave supporting evidence that these 
two new BP adducts are in fact BP tetrols, and formed from the less carcinogenic BPDE 
III. Since these adducts appears to be of biological origin, they should be included when 
using BP tetrols from plasma proteins as biomarkers of BP exposure. To our knowledge, 
there are no studies indicating that these adducts have been used as biomarkers. 
The Ahr knockout mice model were used to study the metabolism of BP; 
specifically the relationship between Ahr genotype and bioactivation of BP in internal 
organs. Interestingly, the lack of a functional Ah receptor results in a slower clearance of 
BP and higher levels of DNA and protein adducts in the Ahr knockout mice. At the same 
time, the presence of a functional Ah receptor seems to be beneficial for the detoxification 
of BP in the Ahr(+/+) mice. Although, the distribution and levels of BP and BP-protein 
adduct are clearly dependent on the route of exposure. As the skin exposure experiment 
showed, the Ahr(+/+) mice did actually have higher levels of protein adducts, but only in 
the exposed skin site. These results indicate that the Ahr(-/-) mice have an Ahr-
independent biotransformation of BP that may involve constitutive levels of Cyp1b1 and 
other oxidative enzymes. Since BP protein adducts may be used as cancer risk markers, 
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there will be need for further studies to clarify the persistence of BP adducts in the Ahr(-/-) 
mice, and their relation to cancer.  
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The present work displays capillary liquid chromatographic column switching methodology
tailored for determination of benzo[a]pyrene tetrol isomers in biological matrices using on-line
fluorescence and m-electrospray ionization mass spectrometric detection. A well-established
off-line crude solid phase extraction procedure was used in order to make the method compatible
with several biological matrices. The solid phase extraction eluates were evaporated to dryness,
redissolved in 1.0 ml methanol : water (10 : 90, v/v), loaded onto a 0.32 mm I.D.6 40 mm 5 mm
Kromasil C18 pre-column for analyte enrichment and back-flushed elution onto a 0.30 mm I.D.6
150 mm 3.5 mm Kromasil C18 analytical column. The samples were loaded with a flow rate of
50 ml min21 and the tetrols were separated at a flow rate of 4 ml min21 with an acetonitrile : 10 mM
ammonium acetate gradient from 10 to 90%. A sample loading flow rate up to 50 ml min21 was
allowed. The fluorescence excitation and emission were set to 342 and 385 nm, respectively,
while mass spectrometric detection of the benzo[a]pyrene tetrols was obtained by monitoring
their [M2H]2molecular ions atm/z 319. The method was validated over the concentration range
0.1–50 ng ml21 benzo[a]pyrene tetrols in a cell culture medium with 100 ml injection volume,
fluorescence detection and the first eluting tetrol isomer as model compound, resulting in a
correlation coefficient of 0.993. The within-assay (n 5 6) and between-assay (n 5 6) precisions
were determined to 2.6–8.6% and 3.8–9.6%, respectively, and the recoveries were determined to
97.9–102.4% within the investigated concentration range. The mass limit of detection (by
fluorescence) was 3 pg for all the tetrol isomers, corresponding to a concentration limit of
detection of 30 pg ml21 cell culture medium. The corresponding mass spectrometric mass limits of
detection were 4–10 pg, corresponding to concentration limits of detection of 40–100 pg ml21 cell
culture medium.
1. Introduction
Polycyclic aromatic hydrocarbons (PAHs) formed during
incomplete combustion of fossil fuels and other organic matter
are among the most widespread environmental carcinogens.1,2
The highest concentrations of PAHs are found in occupational
atmospheres, posing a threat to exposed workers in industries
such as coke- and aluminum-plants, iron- and steel-foundries,
and rubber- and oil-manufacturing factories.1 Workers are
exposed to PAHs through inhalation, skin contamination and
ingestion,1 and at least 11 PAHs are carcinogenic to experi-
mental animals, based on the International Agency for
Research on Cancer (IARC) criteria for carcinogenicity.2
Upon metabolism PAHs are converted into electrophiles
capable of binding covalently to DNA, RNA and proteins.
The formation of DNA-adducts is generally believed to be the
initial step in PAH-induced carcinogenesis.3,4
Benzo[a]pyrene (B[a]P) is the best-studied carcinogenic
PAH, and is metabolized in several organs by cytochrome
P450 monooxygenases to the ultimate carcinogenic
diolepoxide r-7,t-8-dihydrodiol-t-9,10-oxy-7,8,9,10-tetrahy-
drobenzo[a]pyrene (BPDE-I) and to the less carcinogenic
isomer r-7,t-8-dihydrodiol-c-9,10-oxy-7,8,9,10-tetrahydroben-
zo[a]pyrene (BPDE-II).5,6 BPDE-I reacts both with DNA
and proteins to form adducts.3,4,7 Several studies have
employed B[a]P tetrols that are liberated upon acid or
enzymatic hydrolysis of BPDE DNA— or protein adducts in
biological materials isolated from exposed individuals, in order
to quantify B[a]P adducts.7–9 In addition to potential adduct
formation in the body, the unstable and reactive BPDEs are
further metabolized by epoxide hydrolases to B[a]P tetrols
(Fig. 1).10 The bulk part of the excreted B[a]P tetrols is likely
to originate from hydrolyzed BPDE, but a relation between
BPDE adducts and the excreted B[a]P tetrols is also
plausible.11 Determination of B[a]P tetrols in excreta or after
liberation from DNA and proteins is thus a promising
approach for biomonitoring of PAH exposure, and both
conventional gas chromatographic (GC) and liquid chromato-
graphic (LC) methods have been employed for this purpose
in combination with a range of sample preparation pro-
cedures.8,9,11–13 The LC approaches are usually combined
with fluorescence detection in order to obtain sufficient*pal.molander@stami.no
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sensitivity.8,9,14 As the sample amounts in such cases often are
low and the concentrations of the B[a]P tetrols also often are
correspondingly low, biomonitoring of B[a]P tetrols needs
highly sensitive analytical techniques. Miniaturization is often
a key word in developing maximum sensitivity with limited
sample amounts.
Compared to the use of conventional columns, packed
capillary LC with column inner diameters ranging from 500
to 50 mm has offered enhanced mass sensitivity due to
reduced dilution of the chromatographic band.15,16 Further
improvements in concentration sensitivity are accessible
with focusing techniques and column switching systems,16–21
making time-efficient large volume injections and potentially
total sample exploitation available, in addition to on-line
sample clean up. Furthermore, the low flow rates used with
miniaturized LC columns are especially attractive with
regard to electrospray ionization (ESI) mass spectrometry
(MS) coupling.22 Wang et al. have recently shown the
potential of using miniaturized LC-MS for identification
and characterization of urinary B[a]P metabolites from
highly exposed mice and rat.23,24 However, they did not
exploit the potential of large volume injections and column
switching methodology in order to optimize concentration
sensitivity.
The aim of this study was to develop robust and applicable
analytical methodology for determination of B[a]P tetrols in
various biological matrices by means of a combination of
sample enrichment column switching capillary LC with
on-line fluorescence and MS detection to obtain an optimized
system with regard to separation, sensitivity and structural
information.
2. Materials and methods
2.1. Materials and reagents
HPLC grade acetonitrile (ACN) and methanol (MeOH) were
obtained from Rathburn Chemicals (Walkerburn, UK). 96%
Ethanol (EtOH) was purchased from Arcus (Oslo, Norway).
Water was obtained from an Elgastat Maxima HPLC water
purification system (Elga Ltd., Buckinghamshire, UK).
Ammonium acetate (NH4Ac, analytical grade) was provided




trol (B[a]P tetrol II-1), (¡)-benzo[a]pyrene-r-7,t-8,c-9,10-tetra-
hydrotetrol (B[a]P tetrol II-2) were obtained from the National
Cancer Institute, Chemical Carcinogen Repository (Kansas
City, MO, USA). All fused-silica capillaries were purchased
from Polymicro Technologies (Phoenix, AZ, USA). Nitrogen
was obtained from a Whatman nitrogen generator (Haverhill,
MA, USA).
Human hepatoma cell lines HepG2 were obtained from
American Type Culture Collection (Manassas, Virginia, US),
while Dulbecco’s modified eagle medium (DMEM), gluta-
mine, penicillin/streptomycin (PS) and foetal bovine serum
(FBS) were purchased from Gibco BRL (Paisley, Scotland).
Dimethyl sulfoxide (DMSO) and B[a]P were obtained from
Fluka (Buchs, Switzerland).
2.2. Chromatographic system
The analytical column (0.3 6 150 mm, 3.5-mm Kromasil C18)
and the enrichment pre-column (0.32 6 40 mm, 5-mm
Kromasil C18) were provided by G&T Septech (Kolbotn,
Norway). A Waters capillary CapLC2 System (Milford, MA,
USA) with a binary gradient pump was used to deliver the
mobile phase providing back-flushed desorption from the pre-
column and elution on the analytical column. A Model L-7100
(Hitachi Ltd, Tokyo, Japan) isocratic pump was used for
sample loading. A Valco Model C4 injection valve or a
Rheodyne Model 7125 injection valve (Cotati, CA, USA)
(valve1) was used for manual injections of sample volumes of
0.05–1000 ml. A Valco Model CN2 six-port nano-volume
valve served as the column-switching valve. The mobile
phase gradient initial composition was ACN : 10 mM NH4Ac
(90 : 10, v/v) with a linear gradient to 40% ACN in 26 minutes,
followed by a washing step to 90% ACN. The volumetric flow
rate was 4 ml min21 throughout the study, while the MeOH :
water (10 : 90, v/v) sample loading solvent mixture was
delivered at a flow rate of 50 ml min21. The chromatographic
system was operated at ambient temperature. The 10 mM
NH4Ac was filtered through a Millex
1-GS 0.22 mm filter
Fig. 1 Metabolism pattern of B[a]P.
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(Millipore, Billerica, MA, US) daily in order to prevent
clogging of the analytical column.
An Argos 250B (Flux Instruments, Basel, Switzerland)
fluorescence detector equipped with a capillary LC cell with a
20 nl illuminated volume was used for fluorescence detection.
The F detector was operated at an excitation wavelength of
342 nm set by an external monochromator and with an
emission filter with a nominal cut-off wavelength of 385 nm
(50% transmission).
A tandem quadrupole MS equipped with a Z-spray atmo-
spheric pressure ionization ion source prepared for ESI from
Micromass (Manchester, UK) was used for MS analysis, with
a m-ESI stainless steel capillary of 26 mm I.D. Negative mode
ESI single ion recording (SIR) of the B[a]P tetrols at [M 2 H]2
m/z 319 was performed with the applied voltages: capillary
voltage: 23.0 kV; sample cone voltage: 225.0 V; and
extraction cone voltage: 24.0 V. The nebulizer gas flow was
90 l h21, the desolvation gas flow was 360 l h21, the
desolvation temperature was 300 uC and the source tempera-
ture was 90 uC. The capillary LC system and the tandem
quadrupole MS instrument were controlled and data were
acquired using MassLynx v3.5 software, and mass spectra
were acquired in the m/z range 100–500.
2.3. Standard solutions and sample preparation
Stock solutions of the B[a]P tetrols were prepared in EtOH at a
concentration of 1.0 mg ml21, from which all working solutions
were prepared. In the final method, the sample solvent com-
position was MeOH : water (10 : 90, v/v), and LC calibration
solutions were accordingly prepared in the concentration range
0.1–50 ng ml21. In order to exploit the method for determina-
tion of B[a]P tetrols in several biological matrices such as
urine, acid/enzymatic hydrolysis solutions or cell culture
media, where the various matrices most probably would
influence differently the sample enrichment efficiency, a well-
documented, crude off-line solid phase extraction (SPE)
procedure was performed on Sep-Pak Plus C18 cartridges
(Waters).25 The SPE cartridges were washed with neat water
and eluted with neat MeOH, and the eluates were evaporated
to dryness under a stream of nitrogen prior to redissolution in
100 ml MeOH and dilution with water to a total volume of
1.0 ml to obtain the final focusing sample solvent composition.
Validation solutions in the concentration range 0.1–
50 ng ml21 (n 5 5) were prepared by spiking B[a]P tetrol I-1
to cell culture media, of which replicates of 1.0 ml were
subjected to off-line SPE procedure. B[a]P tetrols are sensitive
to heat, light, air, and acids, and all solutions were accordingly
stored in a freezer at 218 uC prior to analysis.
2.4. Sample
Human hepatoma cell line HepG2 was grown to confluence in
150 mm dishes in DMEM containing 1% glutamine, 1% PS
and 10% FBS. All cells were maintained at 37 uC in a
humidified 5% CO2 atmosphere. Cells were exposed to 20 mM
B[a]P (dissolved in DMSO with a 0.05% final concentration)
for 2 days. The 10 ml medium volume from the flask was
recovered at the end of the incubation period and stored at
220 uC. In this case, an aliquot of 100 ml of medium was taken
for crude SPE clean-up and subsequent determination of B[a]P
tetrols by the developed method.
3. Results and discussion
In industries where workers are exposed to PAHs, the level of
exposure is related to their working procedures and tasks.
Thus, there is a need for selective and sensitive analytical
biomonitoring methods covering a wide concentration range in
order to obtain a measure of the exposure to individuals with
different working tasks. Especially when DNA adducts are
used as biomarkers for exposure the need for sensitivity is
often a necessity.26 Furthermore, the non-occupational related
exposure to PAHs for non-smokers is minute, even in urban
areas, which adds further to the need for analytical sensitivity
for biomonitoring of environmental PAH exposure. When
keeping in mind that PAH metabolites originating from
more than three rings to a large extent are excreted in the
faeces,27 it becomes evident that biomonitoring of B[a]P tetrols
in biological fluids would benefit from methods with high
sensitivity, such as miniaturized LC.
3.1. Optimization of separation
LC mobile phase optimization with ESI-MS detection is
usually more challenging than with UV or fluorescence
detectors, due to the fact that the MS signal is strongly
dependent on the ionization efficiency of the solutes, depend-
ing on mobile phase properties. Since the B[a]P tetrols are
sensitive to acids,7,28 commonly used LC-MS mobile phase
additives like acetic and formic acid are best avoided. Thus,
only NH4Ac at concentrations of 0, 5, 10 and 20 mM was
evaluated in the present study in combination with isocratic
mobile phase compositions of MeOH : water (40 : 60, v/v) or
ACN : water (40 : 60, v/v), in order to determine the mobile
phase composition providing the best MS signal-to-noise (S/N)
ratio. The isomer B[a]P tetrol I-1 (Fig. 1) was employed for this
purpose, since B[a]P tetrol I-1 is the isomer found in highest
concentrations in biological samples.29,30 Solutions containing
0.2 mg ml21 B[a]P tetrol I-1 dissolved in the various mobile
phase compositions were introduced to the MS by direct
infusion at a flow rate of 4 ml min21 and mass spectra were
acquired over 1 min. A NH4Ac concentration of 10 mM
provided maximum signal intensity both in combination with
ACN or MeOH as organic modifiers. However, the signal
intensity with the ACN containing mobile phase was approxi-
mately two orders of magnitude higher than with the MeOH
containing mobile phase. Thus, ACN in combination with
10 mMNH4Ac was chosen as organic modifier in further work.
Based on the high bonding density and experiences from
previous work,19 3.5 mm Kromasil C18 was employed as the
stationary phase material on the analytical column. A mobile
phase gradient with an initial composition of ACN : 10 mM
NH4Ac (90 : 10, v/v) followed by a linear gradient to 40%
ACN in 26 minutes provided optimized conditions for the
separation of the B[a]P tetrols at flow rate of 4 ml min21 on the
0.36 150 mm column when using an injection volume of 50 nl.
An additional washing step to 90% ACN was included in order
to elute more retained compounds, such as other PAHs or
metabolites.
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3.2. Optimization of detection
With regard to fluorescence detection optimization, excitation
at various UV maximum wavelengths was evaluated, and
excitation at the highest UV maximum at 342 nm resulted in
the highest signal-to-noise ratio in combination with an
emission filter with a nominal cut-off wavelength of 385 nm
(50% transmission). The fluorescence detector was coupled
in-line between the analytical column and the MS by fused
silica capillaries of 50 mm I.D. of less than 50 cm length in
order to minimize extra-column volumes potentially resulting
in reduced MS sensitivity.
In m-ESI-MS the needle orifice diameter is reduced as
compared to conventional ESI, resulting in the emission of
much smaller primary droplets that undergo subsequent
droplet fissions and evaporation, finally resulting in ion
emission. The miniaturized ESI sources have several advant-
ages compared to conventional ESI sources, such as enhanced
ionization efficiency and higher tolerance toward salt concen-
tration, which can be of importance when working with
biological matrices. In the present study a stainless steel
capillary of 26 mm I.D. was employed, especially compatible
with flow rates in the low ml min21 range. The needle tip in
m-ESI is typically located closer to the MS inlet lenses as
compared to conventional bore ESI capillaries operated with
higher flow rates, often resulting in improved ion extraction.22
The ESI capabilities of the B[a]P tetrol isomers were
investigated individually by dissolving the isomers in ACN :
10 mM NH4Ac (40 : 60, v/v) followed by direct infusion
experiments. Ionization in both positive and negative mode
was initially explored. However, positive ESI was excluded due
to very low ionization as compared to negative mode. These
results are in contrast to the studies by Wang et al.,23,24 where
positive ESI were employed. Maximum [M 2 H]2 (m/z 319)
MS signal intensities for the various B[a]P tetrol isomers were
obtained at partly different operating ESI conditions, illu-
strated by increased in-source fragmentation of one of the
isomers at cone voltages not capable of ionizing other isomers
sufficiently. Due to the narrow separation window of the
isomers, MS signal optimizing was conducted with special
emphasis on obtaining sufficient signal intensities at m/z 319
for all isomers. In general, a stable signal was obtained with
increasing capillary voltages up to 23.0 kV, while in-source
fragmentation was best avoided at cone voltages below 225 V,
when using an optimized extractor cone voltage of 24.0 V and
ion source and desolvation temperatures of 90 and 300 uC,
respectively. Multiple reaction monitoring (MRM) experi-
ments after fragmentation to m/z 301 (2H2O) or 283 (22 H2O)
resulted in an overall reduced sensitivity as compared to SIR
at m/z 319. Thus, SIR at m/z 319 was used in the final
MS method.
3.3 Large volume injection
The main advantage of using miniaturized LC is the increased
mass sensitivity, which is beneficial when only limited sample
amounts are available. This advantage is, however, only of
practical value if a substantial part of the limited sample is
introduced to the chromatographic system, often implying
enrichment of sample volumes that are larger than the 50 nl
injection volumes which are convenient with capillary columns
of y0.3 mm I.D. Furthermore, low flow rates are beneficial
only with concentration sensitive detectors, implying that
miniaturized LC is not beneficial with regard to sensitivity
when using mass-flow sensitive detectors. Fortunately, both
ESI-MS at low rates and fluorescence detectors operate
according to concentration sensitive principles.22
The relative high hydrophobicity of the B[a]P tetrols
requires the presence of an organic modifier in the sample
focusing solution in order to avoid precipitation of the solutes.
This requirement imposes that a stationary phase material
providing high retention of the B[a]P tetrols is preferred in order
to obtain sufficient sample enrichment capabilities particularly
with high sample loading flow rates. 5-mm Kromasil C18
particles provide a compromise between sample capacity and
column backpressure during sample loading at elevated flow
rates. Despite the fact that similar alkyl ligands were used on
both the analytical column and the pre-column, the use of 5-mm
pre-column particles has a potential of providing reconcentra-
tion of the solutes on the analytical column containing 3.5 mm
particles, and was thus used as the pre-column stationary phase
material. The 0.32mm I.D. pre-columnwas of a length of 40mm
in order to be easily mounted in the switching valve.
Methanol as an organic modifier in the focusing sample
solution resulted in slightly higher retention of the B[a]P tetrols
on the pre-column as compared to ACN, while still providing
similar solubility. A standard mixture of the four B[a]P tetrol
isomers was dissolved in aqueous solvent mixtures with MeOH
content of 5, 10, 15 and 20%, and an expanded injection
volume of 100 ml of the sample solutions was injected using the
total column switching system and a flow rate of 4 ml min21.
The peak widths at half peak height and the peak resolutions
were measured with the different sample focusing composi-
tions. For this purpose a fluorescence detector was employed.
The peak widths were constant within the 5–20% MeOH
content interval, while the baseline separation between B[a]P
tetrol II-2 and B[a]P tetrol II-1 was not preserved when
increasing the MeOH content from 10 to 15%. The peak
resolution declined further when the MeOH content was
increased to 20% (Fig. 2). Thus, a composition of MeOH :
water (10 : 90, v/v) was used as sample focusing solution in the
final method. Peak area measurements when comparing 100 ml
injection volumes using this sample focusing composition with
50 nl injections with equal absolute mass, dissolved in neat
MeOH, yielded identical peak areas, confirming complete
dissolution of the B[a]P tetrols in this final sample focusing
composition and no break-through.
Injection of large sample volumes using a loading flow rate
of 4 ml min21 is a time consuming process. However, due to the
low column backpressure on the pre-column, higher flow rates
were applicable within the pressure limits of the chromato-
graphic system. Elevated loading flow rates might, however,
destroy the sample focusing process, potentially resulting in
band broadening or sample break-through. A loading flow
rate of 50 ml min21 was applicable with the final sample
focusing composition used in the present study without
exceeding the pressure limits of the system. Identical peak
shapes, peak resolutions and peak areas were obtained when
injecting 100 ml using a loading flow rate of 50 ml min21 as
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compared to when loading at 4 ml min21. Thus, a loading flow
rate of 50 ml min21 was used in the final method, reducing
the loading time from 25 to 2 minutes. Fig. 3 shows the
chromatographic profiles of a standard mixture of the B[a]P
tetrols when using the final column switching methodology
with fluorescence and MS detection.
In order to examine if injection of volumes larger than 100 ml
were applicable with the final column switching methodology,
a sample volume of 1 ml was loaded at 50 ml min21. The peak
shapes and peak resolutions were comparable to the 100 ml
injections, and the peak areas were 10 times larger, supporting
the fact that injection of sample volumes up to at least 1 ml
is applicable with this method for further improvement of
concentration sensitivity.
3.4. Method validation
As pointed out earlier, B[a]P tetrols can be present in various
biological matrices, mainly in excreta or after liberation from
DNA and proteins. A well-documented, crude off-line reversed
phase SPE method has in a number of studies been employed
for off-line sample pre-treatment of B[a]P tetrols from various
matrices.25 As biological matrices might differently influence
the pre-column sample enrichment, this off-line SPE method
was used in the present study as well, in order to obtain a
sensitive analytical methodology suitable for a maximum
number of applications. In the method validation, aqueous
cell culture media solutions served as a model matrix, to
which exact amounts of B[a]P tetrols were spiked. After
SPE elution, the eluates were evaporated to dryness and
redissolved in 1.0 ml of the final sample focusing solution,
whereof 100 ml was injected with a loading flow rate of
50 ml min21. The first eluting isomer, B[a]P tetrol I-1, served as
a model compound in the precision and recovery experiments,
with fluorescence detection.
The total method was validated in the concentration range
0.1–50 ng ml21 B[a]P tetrol I-1 in cell culture medium. The
method was linear within the investigated concentration range
with a coefficient of correlation of 0.993.
The within- and between-assay precision were established by
injecting six sets of samples at three spike concentration levels
(0.1, 25 and 50 ng ml21) within one and six days, respectively,
by the same analyst. The within-assay (n 5 6) and between-
assay (n 5 6) precision was in the range 2.6–8.6 and 3.8–9.6%,
respectively, as summarized in Table 1.
The recoveries of B[a]P tetrol I-1 were established by
comparing the resulting peak areas from 100 ml column-
switching injections of validation solutions with 100 ml injec-
tions of the LC calibration solutions directly onto the analytical
column (n 5 3). The recoveries at the different concentration
levels were in the range 97.9–102.4%, as summarized in Table 1.
Fig. 2 Chromatographic profiles of the B[a]P tetrols using an injec-
tion volume of 100 ml and a focusing sample solution composition of
water : MeOH (90 : 10, v/v) (a) and water : MeOH (80 : 20, v/v) (b)
(fluorescence detection). Elution order: B[a]P tetrol I-1 (1), I-2 (2), II-2
(3) and II-1 (4).
Fig. 3 Column-switching capillary LC-fluorescence (a) and LC-MS
(b) profiles of the B[a]P tetrols using 100 ml injection volume. Elution
order: B[a]P tetrol I-1 (1), I-2 (2), II-2 (3) and II-1 (4).
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The mass limit of detection (mLOD) of the total method was
3 pg (S/N 5 3) for all the B[a]P tetrol isomers when using
fluorescence detection, corresponding to a concentration limit
of detection (cLOD) of 30 pg ml21 cell culture medium when
using a 100 ml injection volume and 1.0 ml cell culture initial
volume. Since the method is capable of introducing at least 1 ml
sample volumes, the cLOD can potentially be improved by a
factor of 10. The mLODs when using ESI-MS detection were
7, 5, 10 and 4 pg for B[a]P tetrol I-1, I-2, II-1 and II-2,
respectively, corresponding to cLODs of 70, 50, 100 and
40 pg ml21 cell culture medium with 100 ml injection volume
and 1.0 ml cell culture initial volume. The LC-ESI-MS mLODs
are improved by a factor of about 10 as compared to the study
by Wang et al. who recently reported negative ESI LC-MS
mLODs of B[a]P metabolites in the range 40–60 pg.23
The within- and between-assay precision of retention times
were below 1% RSD, and the column efficiency remained
invariant throughout the study. The same pre-column
and analytical column was used throughout the study, and
identical chromatographic performance was observed when
the pre-column and the analytical column were replaced with
columns prepared identically. All calibration, validation and
pre-treated real sample solutions were stable for at least two
months when stored in the dark at 218 uC.
3.5. Determination of B[a]P tetrols in cell culture medium
Cell culture is a frequently used model system to study bio-
transformation and molecular effects of carcinogenic com-
pounds like PAHs.30 In order to monitor the time dependence
of biotransformation reactions, analytical methodology based
on full sample exploitation enables the capture of small cell
medium volumes from on-going biotransformation reactions
without disturbing growth by large reduction of the cell culture
volumes. A 100-ml aliquot of the 10-ml total cell culture
medium volume was incubated for two days, in order to
illustrate the applicability of the method, and Fig. 4 shows the
resulting LC-MS chromatogram. The determined amounts of
the B[a]P tetrols in the samples when injecting 100 ml of the
total 1.0 ml redissolved SPE eluate were 179, 8, 53 and 35 pg
of B[a]P tetrol I-1, I-2, II-1 and II-2, respectively, correspond-
ing to a cell medium concentration of 17.9, 0.8, 5.3 and
3.5 ng mL21, respectively.
4. Conclusion
This paper describes a sensitive and selective miniaturized LC
method for determination of B[a]P tetrols using robust sample
enrichment methodology. The implemented well-documented
off-line SPE procedure offers crude sample clean up, making
the method compatible with most biological matrices of
various nature, although the demonstration of the applicability
of the method in the present study is limited to cell culture
medium matrices only. The column switching method can
easily be automated for high throughput analysis of large
sample series and subsequent assessment of PAH exposure in
groups of individuals of particular interest. The developed
column switching system might also be modified to include the
determination of other B[a]P metabolites in various matrices.
In such cases, application of larger sample volumes can
potentially improve the cLODs of the method. The method is
to be used for measurement of low-dose PAH exposure of
workers from relevant industries.
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